% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Chen:169169,
      author       = {X. Chen$^*$ and F. Guo$^*$ and M. Hoffmeister$^*$ and J.
                      Chang-Claude$^*$ and H. Brenner$^*$},
      title        = {{N}on-steroidal anti-inflammatory drugs, polygenic risk
                      score and colorectal cancer risk.},
      journal      = {Alimentary pharmacology $\&$ therapeutics},
      volume       = {54},
      number       = {2},
      issn         = {0269-2813},
      address      = {Oxford},
      publisher    = {Blackwell Science},
      reportid     = {DKFZ-2021-01298},
      pages        = {167-175},
      year         = {2021},
      note         = {#EA:C070#LA:C070# / 2021 Jul;54(2):167-175},
      abstract     = {The regular use of non-steroidal anti-inflammatory drugs
                      (NSAIDs) has been associated with reduced colorectal cancer
                      (CRC) risk.To explore whether this association varies
                      according to background polygenic risk for CRC.Data were
                      collected from a large population-based case-control study
                      on CRC in Germany. A polygenic risk score (PRS) based on 140
                      CRC-related risk loci was used to quantify the genetic risk.
                      The associations of regular use of NSAIDs (≥2times per
                      week for at least 1 year) with CRC risk were estimated in
                      the whole population and in subgroups according to PRS
                      levels using multivariable logistic regression. The impact
                      of NSAIDs on CRC risk was compared to PRS using the 'genetic
                      risk equivalent' (GRE), a recently developed metric for
                      effective risk communication.In total 5129 CRC cases and
                      4093 controls were included in this analysis. The regular
                      use of NSAIDs (including aspirin) was associated with
                      reduced CRC risk [odds ratio (OR) 0.66, $95\%$ confidence
                      interval (CI) 0.59, 0.74], as was regular use of aspirin
                      only (OR 0.73, $95\%$ CI 0.65, 0.83), without indication of
                      interaction with the PRS (P = 0.10 and 0.22 respectively).
                      The effect of NSAID use was equivalent to the effect of
                      having a 32 percentiles lower PRS (GRE -32, $95\%$ CI -41,
                      -22).The regular use of NSAIDs is associated with greatly
                      reduced CRC risk regardless of individual genetic profile.
                      With an equivalent reduction of relative risk across all
                      polygenic risk groups, absolute risk reduction would be
                      expected to be strongest among those with the highest
                      polygenic risk score.},
      cin          = {C070 / C020 / HD01 / C120},
      ddc          = {610},
      cid          = {I:(DE-He78)C070-20160331 / I:(DE-He78)C020-20160331 /
                      I:(DE-He78)HD01-20160331 / I:(DE-He78)C120-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:34114659},
      doi          = {10.1111/apt.16438},
      url          = {https://inrepo02.dkfz.de/record/169169},
}